Neotame vs Acesulfame Potassium: which is worse?

What is Neotame?

Neotame is a synthetic dipeptide sweetener — a derivative of aspartame with a 3,3-dimethylbutyl group added to block aspartame's metabolism, preventing the release of phenylalanine. This means it is safe for people with phenylketonuria (PKU), unlike aspartame. It is approximately 7,000-13,000 times sweeter than sucrose.

What is Acesulfame Potassium?

Acesulfame potassium (Ace-K) is a calorie-free synthetic sweetener approximately 200 times sweeter than sucrose. It contains a potassium atom bonded to an oxathiazinone dioxide ring structure. It is heat-stable and non-metabolized, passing through the body unchanged. Often blended with sucralose or aspartame to mask bitter aftertaste.

Documented risks

Neotame: Neotame is one of the newer synthetic sweeteners with a shorter safety track record. A 2023 study published in Frontiers in Nutrition found that neotame damaged intestinal epithelial cells in vitro and disrupted the gut microbiome in mice — including reducing beneficial bacteria and increasing bacterial invasion of intestinal cells. The study observed effects at concentrations that could be achievable through high consumption of neotame-containing products. The FDA has set an ADI of 0.3 mg/kg/day, one of the lower sweetener ADIs, reflecting a conservative safety margin. Limited long-term human safety data exist compared to aspartame, acesulfame K, or saccharin, which have been used for decades. EFSA's 2010 opinion found no safety concern at permitted levels. The Frontiers in Nutrition 2023 gut study represents new concerning findings that warrant further investigation.

Acesulfame Potassium: The safety database for Ace-K is considered less comprehensive than that for other sweeteners. Critics have argued that the original FDA approval studies from the 1970s-1980s were insufficient in quality and length to definitively establish long-term safety. The Center for Science in the Public Interest (CSPI) has petitioned for additional testing. Two rat studies found statistically significant increases in lung tumors (in male rats) and mammary tumors at high doses. Regulatory agencies have argued these doses far exceeded typical human exposure and attributed the tumor findings to other factors. However, the question of whether Ace-K's approval studies meet modern standards has been raised by independent researchers. A 2021 study in Cell found that Ace-K and other non-nutritive sweeteners altered gut microbiome composition and affected glucose tolerance in some human participants. Ace-K specifically was associated with changes in gut bacteria that correlated with glycemic effects. Neurological concerns: some animal studies suggest Ace-K may affect brain neurotransmitter systems. A 2013 study in PLoS ONE found that Ace-K consumption in pregnant mice altered offspring postnatal taste preference and increased weight gain, suggesting potential transgenerational effects. These findings were at doses exceeding typical human intake. Endocrine disruption potential has been raised in some in vitro studies, but comprehensive human data are lacking.